Viktor Drvota
Head, Life Science @ SEB Venture Capital
Stockholm, Sweden
Viktor Drvota is a venture - series unknown investor at SEB Venture Capital in Stockholm focused on Medical and Biotechnology. Viktor Drvota is the CEO at Karolinska Development AB. Viktor attended Karolinska Institutet.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 44%
Last updated:
For AI agents: llms.txt
Industries Viktor Drvota invests in
Stages Viktor Drvota invests in
Countries Viktor Drvota invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 5 (56%)
- Biotechnology 5 (56%)
- Biopharma 4 (44%)
- Health Care 1 (11%)
- Therapeutics 1 (11%)
Stage
- Venture - Series Unknown 3 (33%)
- Seed 2 (22%)
- Series B 1 (11%)
- Funding Round 1 (11%)
- Private Equity 1 (11%)
Country
- Sweden 3 (33%)
- Denmark 3 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| BOOST Pharma is a biotechnology research company developing a stem cell therapy for the treatment of osteogenesis imperfecta. It is based on novel mesenchymal stem cells that have high bone-forming capabilities that migrate to the bone of patients where they will engraft, and start bone formation.It was founded in 2019 and is headquartered inCopenhagen, Denmark. | Venture - Series Unknown / May 28, 2024 | ||
| OssDsign was founded in May 2011 by Professor Håkan Engqvist, Dr Thomas Engstrand, Bo Qwarnstrom, Jonas Åberg, Uppsala University AB and other leading clinical, preclinical and materials researchers and engineers. The key people in the company are presented below. OssDsign has in addition developed a network of international experts in ClinicalAffairs, Regulatory and Business Development. | $6.2M / Post-IPO Equity / Nov 29, 2022 | ||
| Henlez uses precise enzymes to create disruptive topical treatments for recurrent follicular skin problems. The company can be reached via mail, phone, or physical address. | $988.4K / Seed / Oct 24, 2022 | ||
| AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure. | Seed / Jun 17, 2021 | ||
| OssDsign was founded in May 2011 by Professor Håkan Engqvist, Dr Thomas Engstrand, Bo Qwarnstrom, Jonas Åberg, Uppsala University AB and other leading clinical, preclinical and materials researchers and engineers. The key people in the company are presented below. OssDsign has in addition developed a network of international experts in ClinicalAffairs, Regulatory and Business Development. | $10.4M / Venture - Series Unknown / Nov 04, 2015 | ||
| InDex Pharmaceuticals AB is a clinical stage biopharmaceutical company building a leading immunotherapy franchise based on its TLR platform (toll-like receptors). It discovers and develops DIMS drugs (DNA-based immunomodulatory sequence) to treat diseases within a variety of therapeutic areas, including inflammation and cancer. | $20M / Venture - Series Unknown / Feb 25, 2014 | ||
| Nuevolution is a leading small molecule lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics®, a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based drug discovery technology. Chemetics® enables rapid synthesis andDNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented quantity, quality and speed compared to existing drug discovery technologies. Nuevolutions library collection currently exceeds 1 billion small molecule compounds and synthetic biologics for screening. Nuevolution partners its technology with pharmaceutical and biotechnology companies. Nuevolution has entered into agreementswith Merck & Co., Lexicon Pharmaceuticals, GlaxoSmithKline, Novartis Pharma and Boehringer Ingelheim. Nuevolution has also entered into a joint venture consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and Professor Kristian Helin (Biotech Research & Innovation Centre, University of Copenhagen) aiming at discovery and development of novel small molecule drugs against epigenetic factors. This $ 4 million budget project is supported by the Danish High Technology Fund. Nuevolution has demonstrated the power of Chemetics® by identifying highly potent and drug like novel ligands with the potential toaddress major unmet medical needs across a range of therapeutic areas and target classes. Nuevolution is a privately owned company by key Scandinavian investors, including Industrifonden, SEB Venture Capital, SunstoneCapital, SLS Invest and Novo A/S. | $12.1M / Jun 19, 2012 | ||
| InDex Pharmaceuticals AB is a clinical stage biopharmaceutical company building a leading immunotherapy franchise based on its TLR platform (toll-like receptors). It discovers and develops DIMS drugs (DNA-based immunomodulatory sequence) to treat diseases within a variety of therapeutic areas, including inflammation and cancer. | $7.2M / Private Equity / Jan 21, 2011 | ||
| Nuevolution is a leading small molecule lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics®, a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based drug discovery technology. Chemetics® enables rapid synthesis andDNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented quantity, quality and speed compared to existing drug discovery technologies. Nuevolutions library collection currently exceeds 1 billion small molecule compounds and synthetic biologics for screening. Nuevolution partners its technology with pharmaceutical and biotechnology companies. Nuevolution has entered into agreementswith Merck & Co., Lexicon Pharmaceuticals, GlaxoSmithKline, Novartis Pharma and Boehringer Ingelheim. Nuevolution has also entered into a joint venture consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and Professor Kristian Helin (Biotech Research & Innovation Centre, University of Copenhagen) aiming at discovery and development of novel small molecule drugs against epigenetic factors. This $ 4 million budget project is supported by the Danish High Technology Fund. Nuevolution has demonstrated the power of Chemetics® by identifying highly potent and drug like novel ligands with the potential toaddress major unmet medical needs across a range of therapeutic areas and target classes. Nuevolution is a privately owned company by key Scandinavian investors, including Industrifonden, SEB Venture Capital, SunstoneCapital, SLS Invest and Novo A/S. | $15M / Series B / Oct 10, 2003 |
Co-Investors
About SEB Venture Capital
SEB Venture Capital is a Fintech investor that helps entrepreneurs and innovators launch and grow profitable businesses. They primarily serve as a strategic corporate venture focused on Fintech investments, with the option of partnering with SEB. They are also on the hunt for game-changing inventive solutions to new technologies that will make the financial industry smarter, safer, and more environmentally responsible, as well as more user-friendly. They also function as an evergreen fund, giving them the flexibility and staying strength to focus on long-term wealth development depending on what is best for the firm and its shareholders.
SEB Venture Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anna Gustafsson
Investment Manager
|
|||
Johan Wolf
Head of SEB Venture Capital
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Viktor Drvota invest in?
Viktor Drvota invests primarily in Medical, Biotechnology and Biopharma startups, most often at Venture - Series Unknown and Seed stage. Most of the 9 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Viktor Drvota?
Public channels for Viktor Drvota include LinkedIn and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Viktor Drvota last invest?
The most recent investment recorded for Viktor Drvota closed in May 2024. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
